Alpha-Thalassaemia — Research Summary
Printed from RareWays (rareways.com.au) on 10 June 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Familial erythrocytosis and phenotypic heterogeneity associated with different defects in alpha globin genes: a significant new case of Hb Wroclaw (α88(F9) Ala>Glu;
Carrai Valentina et al. — Clinical chemistry and laboratory medicine (24 February 2026)
https://pubmed.ncbi.nlm.nih.gov/41622866/
- 2.
Novel serum autoantibodies against alpha thalassemia/mental retardation syndrome X-linked, a component of promyelocytic leukaemia nuclear bodies, in dermatomyositis.
Yamashita Yuta et al. — Rheumatology (Oxford, England) (4 February 2026)
https://pubmed.ncbi.nlm.nih.gov/41206654/
- 3.
Clinical implications of expanded carrier screening for pregnancy-related care and individual health.
Gemmell Laura C et al. — Fertility and sterility (1 February 2026)
https://pubmed.ncbi.nlm.nih.gov/40865753/
- 4.
Exploring the influence of alpha thalassemia on antibody responses to Plasmodium falciparum infections in Ghana
Augustine Boakye Donkor et al. — Research Square (23 December 2025)
https://doi.org/10.21203/rs.3.rs-8231440/v1
- 5.
Hemoglobin alpha-like subunit mu is expressed during ontogeny and is elevated in alpha thalassemia
Kishore Garapati et al. — Blood Red Cells & Iron (15 December 2025)
https://doi.org/10.1016/j.brci.2025.100043
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Alpha-Thalassaemia
Alpha-Thalassaemia is an inherited blood disorder caused by mutations in the alpha-globin genes, resulting in reduced or absent production of haemoglobin alpha chains. It has high prevalence in Southeast Asian and Mediterranean communities in Australia. Severity ranges from silent carrier status to severe haemolytic anaemia (HbH disease) and the life-threatening Haemoglobin Barts hydrops fetalis.
Most Recent Research
Common Questions
What is Alpha-Thalassaemia?
Alpha-Thalassaemia is an inherited blood disorder caused by mutations in the alpha-globin genes, resulting in reduced or absent production of haemoglobin alpha chains. It has high prevalence in Southeast Asian and Mediterranean communities in Australia. Severity ranges from silent carrier status to severe haemolytic anaemia (HbH disease) and the life-threatening Haemoglobin Barts hydrops fetalis.
How many clinical trials are available for Alpha-Thalassaemia?
RareWays currently indexes 6 clinical trials for Alpha-Thalassaemia, of which 3 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Alpha-Thalassaemia come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Alpha-Thalassaemia.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.